Below is an Investor- and Board-Grade GO / NO-GO DECISION MATRIX designed for
Crown Organogenesis Protocols Inc. (COPI).
This matrix integrates technical biology, field performance, economics, and regulatory risk and is suitable for IC review, investor committees, and DENR-linked pilot approvals.

GO / NO-GO DECISION MATRIX

Crown Organogenesis Protocols Inc.

OrgaGen™ | Lab-to-Land™ | RegenCore™ Systems

1. Purpose of the Matrix

To provide a disciplined, objective decision framework that determines whether:

The Pilot Program proceeds to commercial scale,
Requires technical or economic redesign, or
Is halted to prevent capital misallocation.

2. Decision Timing

Formal reviews at:

T₁: 6 months (Establishment Gate)
T₂: 12 months (Performance Gate)
T₃: 24–36 months (Scale-Readiness Gate)

3. Technical GO / NO-GO Criteria

A. Biological Performance

Metric	GO Threshold	CONDITIONAL	NO-GO
Survival Rate	≥85%	75–84%	<75%
Growth Uniformity (CV)	≤15%	16–20%	>20%
Morphological Stability	≥95%	90–94%	<90%
Root System Quality	Robust, uniform	Moderate	Poor / inconsistent
Field Adaptation Time	≤90 days	91–120 days	>120 days

B. RegenCore™ Regeneration Response

Indicator	GO	CONDITIONAL	NO-GO
Post-stress recovery	Strong	Moderate	Weak
Secondary growth	Evident	Limited	Absent
Multi-cycle viability	Demonstrated	Inconclusive	Failed
Physiological resilience	High	Moderate	Low

C. Disease & Biosecurity

Metric	GO	CONDITIONAL	NO-GO
Contamination rate	≤2%	3–5%	>5%
Field disease spread	None	Localized	Systemic
Batch isolation success	Effective	Partial	Failed

4. Financial GO / NO-GO Criteria

A. Unit Economics

Metric	GO	CONDITIONAL	NO-GO
Cost per surviving tree	≤ model +5%	+6–10%	>10%
Maintenance cost/ha	≤ control	+5–10%	>10%
Replacement rate	≤5%	6–10%	>10%
Labor intensity	Reduced	Neutral	Higher

B. Yield & Revenue Proxies

Metric	GO	CONDITIONAL	NO-GO
Yield predictability	High	Moderate	Low
Growth advantage vs control	≥20%	10–19%	<10%
Time-to-value	Accelerated	Neutral	Delayed
Multi-cycle revenue potential	Validated	Partial	Unviable

5. Regulatory & ESG Gate

Category	GO	CONDITIONAL	NO-GO
DENR CNC/ECC alignment	Clear	Minor clarifications	Non-compliant
CITES non-wild proof	Traceable	Partial	Insufficient
ESG indicators	Positive	Neutral	Negative
Community & landowner acceptance	Strong	Mixed	Opposed

6. Integrated Decision Logic

A. AUTOMATIC GO

All technical metrics at GO
≥80% of financial metrics at GO
No regulatory NO-GO flags

→ Proceed to commercial scale

B. CONDITIONAL GO

Technical GO + some CONDITIONAL
Financial metrics within redesign range
No systemic biological failures

→ Proceed with optimization & redesign

C. NO-GO

Any systemic biological failure
Any regulatory NO-GO
Unit economics exceed thresholds materially

→ Terminate or redesign before further capital deployment

7. Risk Escalation Triggers

Immediate escalation if:

Sudden mortality clusters
Unexpected genetic instability
Regulatory reclassification risk
Biosecurity breach
Market collapse impacting economics

8. Governance & Accountability

Scientific Director: biological sign-off
CFO / Investment Lead: economic sign-off
ESG & Compliance Officer: regulatory sign-off
Board / IC: final decision authority

All decisions documented and auditable.

9. Investor-Facing Statement

“Capital is deployed only when biology, economics, and compliance converge. This matrix ensures Crown Organogenesis Protocols Inc. scales with discipline—not optimism.”

10. Strategic Value

This matrix:

Signals institutional seriousness
Reduces downside risk
Accelerates investor confidence
Aligns science with capital allocation

Go / No-Go Decision Matrix